The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index; 37 of the 75 sources its claims cite were checked for support.
Thyroid diseases and bone health
Open accessAbstract
Thyroid hormones are essential for skeletal development and are important regulators of bone maintenance in adults. Childhood hypothyroidism causes delayed skeletal development, retarded linear growth and impaired bone mineral accrual. Epiphyseal dysgenesis is evidenced by classic features of stippled epiphyses on X-ray. In severe cases, post-natal growth arrest results in a complex skeletal dysplasia. Thyroid hormone replacement stimulates catch-up growth and bone maturation, but recovery may be incomplete dependent on the duration and severity of hypothyroidism prior to treatment. A severe phenotype characteristic of hypothyroidism occurs in children with resistance to thyroid hormone due to mutations affecting THRA encoding thyroid hormone receptor α (TRα). Discovery of this rare condition recapitulated animal studies demonstrating that TRα mediates thyroid hormone action in the skeleton. In adults, thyrotoxicosis is well known to cause severe osteoporosis and fracture, but cases are rare because of prompt diagnosis and treatment. Recent data, however, indicate that subclinical hyperthyroidism is associated with low bone mineral density (BMD) and an increased risk of fracture. Population studies have also shown that variation in thyroid status within the reference range in post-menopausal women is associated with altered BMD and fracture risk. Thus, thyroid status at the upper end of the euthyroid reference range is associated with low BMD and increased risk of osteoporotic fragility fracture. Overall, extensive data demonstrate that euthyroid status is required for normal post-natal growth and bone mineral accrual, and is fundamental for maintenance of adult bone structure and strength.
Overview
CoChat Summary
TL;DR
This review summarizes how thyroid hormones regulate skeletal development and adult bone maintenance, with hypothyroidism and hyperthyroidism having opposing effects in children and excess thyroid hormone promoting bone loss in adults. It concludes that euthyroid status is required for normal growth and bone mineral accrual and that thyroid status at the upper end of the euthyroid reference range is associated with lower BMD and increased fragility fracture risk.
Key findings
- In adults, hyperthyroidism causes high bone turnover with increased resorption and formation, shortened remodeling time, and net loss of approximately 10% of bone per remodeling cycle; severe osteoporosis from untreated thyrotoxicosis is now rare because of early diagnosis and treatment.
- In an individual participant meta-analysis of 70,298 subjects from 13 prospective cohort studies (762,401 person-years), subclinical hypothyroidism was not associated with fracture, whereas TSH <0.01 mU/L was associated with 2-fold increased hip fracture risk and 3.5-fold increased spine fracture risk.
- In a meta-analysis of 56,835 subjects (2,565 hip fractures) from 12 prospective cohort studies (659,059 person-years), lower TSH and higher fT4 within the reference range were associated with 22–25% increased risk of hip fracture; in the OPENTHYRO register cohort (222,138 normal-TSH plus 9,217 low-TSH individuals, 7.5 years), each SD decrease in TSH increased hip fracture risk (HR 1.45, p<0.001) and major osteoporotic fracture risk (HR 1.32, p<0.001).
- In post-menopausal women on suppressive T4, meta-analyses showed BMD reduced by 7% at the lumbar spine (CI 4–10%) and 5% at the femur (CI 2–8%), with no prospective fracture data; pre-menopausal women showed no effect on BMD. RTHα is described in 15 THRA mutations in 11 codons affecting 29 individuals from 16 families.
Methods
- Narrative review of published human and mouse literature on thyroid disease and bone, including large individual participant meta-analyses and register-based cohorts; no new primary data are presented.
- The review synthesizes studies of childhood and adult hypothyroidism/hyperthyroidism, subclinical thyroid disease, euthyroid reference-range variation, TSH suppression therapy for thyroid cancer, and genetic disorders of thyroid function (TSHB, TSHR, THRA, THRB).
- Main analysis is qualitative synthesis; no systematic search strategy, inclusion criteria, or formal quality assessment is stated in the text.
Limitations
- The paper states that overall interpretation of adult studies is limited by heterogeneous study design, confounding factors, lack of power, and differing end-point analyses.
- The paper states that there are no good clinical data demonstrating skeletal consequences of hypothyroidism in adults; no fracture data are available for pre-menopausal women on suppressive T4; no prospective fracture data are available for post-menopausal women on suppressive T4; and RTHβ skeletal descriptions are variable and largely restricted to case reports or case series.
- Evident from the text: this is a narrative review without a described systematic search or quality appraisal, so the synthesis may be selective; the paper also notes that targeted prospective clinical trials are still needed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
15 Valid · 1 Not valid · 11 Not checked · 5 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Affected children and adults had a similar spectrum of abnormalities characteristic of the skeletal dysplasia and variable response to T4 treatment reported in individuals with mutations affecting TRα1 alone.”
§ Thyroid diseases and bone health > Skeletal consequences of genetic disorders of thyroid function > Mutations affecting thyroid hormone receptors
What the sources say
- Not checked — no full text of the sourcecites [67] Demir K, van Gucht AL, Buyukinan M, Catli G, Ayhan Y, Nijat Bas V, Dundar B, Ozkan B, Meima ME, Edward Visser W, Peeters RP, Visser TJ (2016) Diverse genotypes and phenotypes of three novel thyroid hormone receptor alpha mutations. J Clin Endocrinol Metab. doi: 10.1210/jc.2016-1404 source
- Partly supportedcites [69] Moran C, Agostini M, Visser WE, Schoenmakers E, Schoenmakers N, Offiah AC, Poole K, Rajanayagam O, Lyons G, Halsall D, Gurnell M, Chrysis D, Efthymiadou A, Buchanan C, Aylwin S, Chatterjee KK (2014) Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients. Lancet Diabetes Endocrinol 2(8):619–626. doi: 10.1016/S2213-8587(14)70111-1 sourceExperimental — accuracy not yet measured
The Abstract Findings and Discussion (pages not available in our copy) describe similar clinical and radiological features in this family and earlier TRα1-only cases. The Results section, “Response to thyroxine therapy,” reports improvement across the three affected patients, with differences among treatment measures. It does not establish that their variable T4 response was similar to the response in TRα1-only cases. (LLM, conf=0.83)
- Could not verifycites [72] van Gucht AL, Meima ME, Zwaveling-Soonawala N, Visser WE, Fliers E, Wennink JM, Henny C, Visser TJ, Peeters RP, van Trotsenburg AS (2016) Resistance to thyroid hormone alpha in an 18-month-old girl: clinical, therapeutic, and molecular characteristics. Thyroid 26(3):338–346. doi: 10.1089/thy.2015.0463 sourceExperimental — accuracy not yet measured
Searches for skeletal dysplasia, variable T4 response, and comparisons with TRα1-only mutations found no matching full-text passage in our copy. The returned material was labeled Abstract and describes improvement in one girl, but does not establish variable responses across affected children and adults or the claimed comparison. (LLM, conf=0.68)
- Supportedcites [76] Moran C, Agostini M, McGowan A, Schoenmakers E, Fairall L, Lyons G, Rajanayagam O, Watson L, Offiah A, Barton J, Price S, Schwabe J, Chatterjee K (2017) Contrasting phenotypes in resistance to thyroid hormone alpha correlate with divergent properties of thyroid hormone receptor alpha1 mutant proteins. Thyroid 27(7):973–982. doi: 10.1089/thy.2017.0157 source
The Introduction identifies the two patients’ mutations as affecting both TRα1 and TRα2. The Results (Response to T4 therapy) report improvement in P1 but little growth response in P2, while the Discussion reports no discernible added phenotype from TRα2 in these patients and compares their treatment responses with those reported for other TRα defects. Page numbers are unavailable in our copy. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Population studies have also shown that variation in thyroid status within the reference range in post-menopausal women is associated with altered BMD and fracture risk.”
§ Thyroid diseases and bone health > Abstract
What the sources say
- Not checked — no full text of the sourcecites [40] Murphy E, Gluer CC, Reid DM, Felsenberg D, Roux C, Eastell R, Williams GR (2010) Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. J Clin Endocrinol Metab 95(7):3173–3181. doi: 10.1210/jc.2009-2630 source
- Not checked — no full text of the sourcecites [41] Grimnes G, Emaus N, Joakimsen RM, Figenschau Y, Jorde R (2008) The relationship between serum TSH and bone mineral density in men and postmenopausal women: the Tromso study. Thyroid 18(11):1147–1155 source
- Not checked — no full text of the sourcecites [42] Hwangbo Y, Kim JH, Kim SW, Park YJ, Park DJ, Kim SY, Shin CS, Cho NH (2015) High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women. Osteoporos Int. doi: 10.1007/s00198-015-3270-3 source
- Not checked — no full text of the sourcecites [43] Kim DJ, Khang YH, Koh JM, Shong YK, Kim GS (2006) Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women. Clin Endocrinol (Oxf) 64(1):86–90 source
- Not checked — no full text of the sourcecites [44] Lin JD, Pei D, Hsia TL, Wu CZ, Wang K, Chang YL, Hsu CH, Chen YL, Chen KW, Tang SH (2011) The relationship between thyroid function and bone mineral density in euthyroid healthy subjects in Taiwan. Endocr Res 36(1):1–8 source
- Not checked — no full text of the sourcecites [45] Mazziotti G, Porcelli T, Patelli I, Vescovi PP, Giustina A (2010) Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 46(3):747–751. doi: 10.1016/j.bone.2009.10.031 source
- Not checked — no full text of the sourcecites [46] Morris MS (2007) The association between serum thyroid-stimulating hormone in its reference range and bone status in postmenopausal American women. Bone 40(4):1128–1134 source
- Not checked — no full text of the sourcecites [47] Noh HM, Park YS, Lee J, Lee W (2015) A cross-sectional study to examine the correlation between serum TSH levels and the osteoporosis of the lumbar spine in healthy women with normal thyroid function. Osteoporos Int 26(3):997–1003. doi: 10.1007/s00198-014-2906-z source
- Supportedcites [48] Roef G, Lapauw B, Goemaere S, Zmierczak H, Fiers T, Kaufman JM, Taes Y (2011) Thyroid hormone status within the physiological range affects bone mass and density in healthy men at the age of peak bone mass. Eur J Endocrinol 164(6):1027–1034 source
The Introduction reports a study of variation in normal-range thyroid status, bone mineral density and fracture susceptibility in postmenopausal women. The Discussion further reports an association between higher thyroid hormone levels and reduced BMD in that population. This paper reports those findings rather than studying postmenopausal women itself. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [49] Svare A, Nilsen TI, Asvold BO, Forsmo S, Schei B, Bjoro T, Langhammer A (2013) Does thyroid function influence fracture risk? Prospective data from the HUNT2 study, Norway. Eur J Endocrinol 169(6):845–852. doi: 10.1530/EJE-13-0546 source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Affected children and adults had a similar spectrum of abnormalities characteristic of the skeletal dysplasia and variable response to T4 treatment reported in individuals with mutations affecting TRα1 alone.”
§ Thyroid diseases and bone health > Skeletal consequences of genetic disorders of thyroid function > Mutations affecting thyroid hormone receptors
What the sources say
- Not checked — no full text of the sourcecites [67] Demir K, van Gucht AL, Buyukinan M, Catli G, Ayhan Y, Nijat Bas V, Dundar B, Ozkan B, Meima ME, Edward Visser W, Peeters RP, Visser TJ (2016) Diverse genotypes and phenotypes of three novel thyroid hormone receptor alpha mutations. J Clin Endocrinol Metab. doi: 10.1210/jc.2016-1404 source
- Supportedcites [69] Moran C, Agostini M, Visser WE, Schoenmakers E, Schoenmakers N, Offiah AC, Poole K, Rajanayagam O, Lyons G, Halsall D, Gurnell M, Chrysis D, Efthymiadou A, Buchanan C, Aylwin S, Chatterjee KK (2014) Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients. Lancet Diabetes Endocrinol 2(8):619–626. doi: 10.1016/S2213-8587(14)70111-1 source
The Results (Clinical Investigation; page unavailable) report a thickened skull vault in all three affected family members. The Findings and Discussion state that their radiological and clinical features were similar to those of previously reported cases with TRα1 defects alone, despite their mutation affecting both TRα1 and TRα2. (LLM, conf=0.88)
- Could not verifycites [72] van Gucht AL, Meima ME, Zwaveling-Soonawala N, Visser WE, Fliers E, Wennink JM, Henny C, Visser TJ, Peeters RP, van Trotsenburg AS (2016) Resistance to thyroid hormone alpha in an 18-month-old girl: clinical, therapeutic, and molecular characteristics. Thyroid 26(3):338–346. doi: 10.1089/thy.2015.0463 sourceExperimental — accuracy not yet measured
No passage from our indexed copy addresses whether mutations affecting both TRα1 and TRα2 produce skeletal abnormalities similar to those seen with TRα1-only mutations. Searches for TRα2, skeletal dysplasia, and related terms returned no relevant passage; the only returned text was bibliographic metadata (labelled Abstract, no page). (LLM, conf=0.72)
- Partly supportedcites [76] Moran C, Agostini M, McGowan A, Schoenmakers E, Fairall L, Lyons G, Rajanayagam O, Watson L, Offiah A, Barton J, Price S, Schwabe J, Chatterjee K (2017) Contrasting phenotypes in resistance to thyroid hormone alpha correlate with divergent properties of thyroid hormone receptor alpha1 mutant proteins. Thyroid 27(7):973–982. doi: 10.1089/thy.2017.0157 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says mutations affecting both TRα1 and TRα2 generally produced no discernible additional phenotype, supporting a broadly similar clinical picture, but notes one case with unusual skeletal features. It describes skeletal dysplasia in one of its two adolescent patients; it does not establish a similar spectrum of skeletal-dysplasia abnormalities across affected children and adults compared with people whose mutations affect TRα1 alone. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Overall, subclinical hyperthyroidism was associated with bone loss and fracture, particularly in individuals with endogenous disease [28].”
§ Thyroid diseases and bone health > Skeletal consequences of thyroid disease in adults > Subclinical thyroid disease
What the sources say
- Partly supportedcites [28] Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Juni P, Aujesky D, Rodondi N, Thyroid Studies Collaboration (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313(20):2055–2065. doi: 10.1001/jama.2015.5161 sourceExperimental — accuracy not yet measured
The Conclusions report increased fracture risk with subclinical hyperthyroidism, particularly in people with endogenous disease. The paper does not establish the claimed association with bone loss: its introduction says subclinical dysfunction could be associated with bone loss, and the Discussion describes bone loss as a possible mechanism rather than a measured outcome. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“More recently, THRA mutations affecting both TRα1 and TRα2 have been described [67, 69, 72, 76].”
§ Thyroid diseases and bone health > Skeletal consequences of genetic disorders of thyroid function > Mutations affecting thyroid hormone receptors
What the sources say
- Not checked — no full text of the sourcecites [67] Demir K, van Gucht AL, Buyukinan M, Catli G, Ayhan Y, Nijat Bas V, Dundar B, Ozkan B, Meima ME, Edward Visser W, Peeters RP, Visser TJ (2016) Diverse genotypes and phenotypes of three novel thyroid hormone receptor alpha mutations. J Clin Endocrinol Metab. doi: 10.1210/jc.2016-1404 source
- Supportedcites [69] Moran C, Agostini M, Visser WE, Schoenmakers E, Schoenmakers N, Offiah AC, Poole K, Rajanayagam O, Lyons G, Halsall D, Gurnell M, Chrysis D, Efthymiadou A, Buchanan C, Aylwin S, Chatterjee KK (2014) Resistance to thyroid hormone caused by a mutation in thyroid hormone receptor (TR)alpha1 and TRalpha2: clinical, biochemical, and genetic analyses of three related patients. Lancet Diabetes Endocrinol 2(8):619–626. doi: 10.1016/S2213-8587(14)70111-1 source
The Molecular Genetic Studies section reports a THRA substitution in the sequence common to TRα1 and TRα2. The Introduction explicitly describes this family's defect as resulting in mutation of both proteins. (LLM, conf=0.95)
- Could not verifycites [72] van Gucht AL, Meima ME, Zwaveling-Soonawala N, Visser WE, Fliers E, Wennink JM, Henny C, Visser TJ, Peeters RP, van Trotsenburg AS (2016) Resistance to thyroid hormone alpha in an 18-month-old girl: clinical, therapeutic, and molecular characteristics. Thyroid 26(3):338–346. doi: 10.1089/thy.2015.0463 sourceExperimental — accuracy not yet measured
No passage from our copy addresses whether the reported THRA mutation affects both TRα1 and TRα2. Searches for the two isoforms, THRA mutations, and receptor-alpha splice variants returned no relevant passage. (LLM, conf=0.70)
- Supportedcites [76] Moran C, Agostini M, McGowan A, Schoenmakers E, Fairall L, Lyons G, Rajanayagam O, Watson L, Offiah A, Barton J, Price S, Schwabe J, Chatterjee K (2017) Contrasting phenotypes in resistance to thyroid hormone alpha correlate with divergent properties of thyroid hormone receptor alpha1 mutant proteins. Thyroid 27(7):973–982. doi: 10.1089/thy.2017.0157 source
The Results (Molecular genetic studies) report two THRA missense mutations involving both TRα1 and TRα2. The Introduction likewise describes both mutations as involving the two proteins, directly supporting the cited claim. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
12 more claims · 7 with their cited sources checked
Create a free account to see all 32 claims and every source verdict.
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and osteoporosis (61).”
From Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism (2020) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Thyroid hormones have profound effects on the skeletal development and bone maintenance, affecting not only the function of osteoclasts and osteoblasts but also participating in the regulation of bone metabolism [3–5].”
From Effects of levothyroxine therapy on bone and mineral metabolism in hypothyroidism: a systematic review and meta-analysis (2025) · cites this paper as [4]
In the citing paper
“Since thyroid hormones have major effects on bone remodeling, LT4 overtreatment may increase bone turnover with higher bone resorption than formation, resulting in progressive bone loss (189).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Yang R, Yao L, Fang Y, Sun J, Guo T, Yang K, Tian L (2017) The relationship between subclinical thyroid dysfunction and the risk of fracture or low bone mineral density: a systematic review and meta-analysis of cohort studies. J Bone Miner Metab. doi: 10.1007/s00774-017-0828-5”
Cited work 10.1007/s00774-017-0828-5 · retracted 2019-08-02 · notice 10.1007/s00774-019-01037-5 · this paper published 2017-08-29
Citations
Cites
1 retracted
Yang, R., Yao, L., Fang, Y., Sun, J., Guo, T., Yang, K., & Tian, L. (2017) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-017-0828-5 · Cited by 40
RetractedDevelopmental regulation of the growth plate
Kronenberg, H. M. (2003) · Nature · doi:10.1038/nature01657 · Cited by 2,849
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer
Mazzaferri, E. L., & Jhiang, S. M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90321-2 · Cited by 2,635
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Cellular and molecular mechanisms of bone remodeling
Raggatt, L. J., & Partridge, N. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.041087 · Cited by 1,402
Mechanisms of thyroid hormone action
Brent, G. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60047 · Cited by 1,244 · cited 1×
“TRs function as hormone-dependent transcription factors that repress target gene expression in the absence of hormone and stimulate gene transcription in response to T3 binding [14].”
BackgroundGenetic Control of Bone Formation
Karsenty, G., Kronenberg, H. M., & Settembre, C. (2009) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.042308.113308 · Cited by 667 · cited 1×
“Long bones and vertebrae, by contrast, form on an intermediary cartilage template by endochondral ossification after mesenchyme precursors differentiate to chondrocytes [3].”
BackgroundREFETOFF, S., DEWIND, L. T., & DEGROOT, L. J. (1967) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-27-2-279 · Cited by 568
Role of Thyroid Hormones in Skeletal Development and Bone Maintenance
Bassett, J. H. D., & Williams, G. R. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1106 · Cited by 540
Self-citation
Cited by
van Trotsenburg, P., Stoupa, A., Léger, J., Rohrer, T., Peters, C., Fugazzola, L., Cassio, A., Heinrichs, C., Beauloye, V., Pohlenz, J., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0333 · Cited by 469
The Role of Osteoclast Energy Metabolism in the Occurrence and Development of Osteoporosis
Da, W., Tao, L., & Zhu, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.675385 · Cited by 177
Törring, O., Watt, T., Sjölin, G., Byström, K., Abraham‐Nordling, M., Calissendorff, J., Cramon, P. K., Nyström, H. F., Hallengren, B., Holmberg, M., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0315 · Cited by 117
Mechanistic advances in osteoporosis and anti‐osteoporosis therapies
Wang, H., Luo, Y., Wang, H., Li, F., Yu, F., & Ye, L. (2023) · MedComm · doi:10.1002/mco2.244 · Cited by 88
D’Ambrosio, F., Amato, A., Chiacchio, A., Sisalli, L., & Giordano, F. (2023) · Dentistry Journal · doi:10.3390/dj11060146 · Cited by 83
Metadata
- Authors
- Williams, G. R., & Bassett, J. H. D.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Williams, G. R.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2017-08-29
- Volume
- 41
- Issue
- 1
- Pages
- 99-109
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- PMC
- PMC5754375
- OpenAlex
- W2752632293
- Semantic Scholar
- 7b574fb9da63eb26bb422cf80784f5083ed98f39
- Cited by
- 276
- References
- 92
- Citations by year
- 2026: 32 · 2025: 35 · 2024: 34 · 2023: 34 · 2022: 36 · 2021: 30 · 2020: 29 · 2019: 26 · 2018: 15 · 2017: 1
- FWCI
- 13.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Endocrinological Investigation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- Wellcome Trust (101123, 110141, 110140)
- Horizon 2020 Framework Programme (666869)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- thyroid dysfunction, bone health, hypothyroidism, childhood hypothyroidism, growth arrest, thyroid hormone replacement, thyroid hormone resistance, thyroid hormone receptor alpha, thyrotoxicosis, osteoporosis, subclinical hyperthyroidism, osteopenia, fracture risk, postmenopausal women, bone mineral accrual, skeletal development
- MeSH terms
- Bone and Bones, Humans, Hypothyroidism, Mutation, Osteoporosis, Receptors, Thyroid Hormone, Thyroid Hormones, Thyrotoxicosis, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-27, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thyroid diseases and bone health. https://app.cochat.ai/papers/10.1007/s40618-017-0753-4
- The paper
- Williams, G. R., & Bassett, J. H. D. (2018). Thyroid diseases and bone health. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-017-0753-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.